ONC-392,Pembrolizumab
biontech,Merck
['sclc', 'nsclc', '$bntx', 'biontech']
biontech $bntx and oncoc4 present positive phase 1/2 data for antibody candidate bnt316/onc-392 (anti-ctla-4) in hard-to-treat nsclc at #asco23 
Biotellytics / https://t.co/37itIfRolp = business intel service on listed European Bios / Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design)